2020-12-02
Camurus announces that Braeburn receives Complete Response Letter for Brixadi for opioid use disorder in the US
Camurus AB today announced that Camurus licensee Braeburn has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its new drug application (NDA) for Brixadi.
Read the full press release: https://www.camurus.com/